Paid plasma donor programs are being criticized, principally on the philosophical grounds that human tissue donations should be freely given and not sold. Philosophically, this argument has merit. But in reality, restricting these programs at this time would be injurious to many patients in the United States and abroad. Restrictions would be particularly damaging to the United States' hemophilia patients.
Hemophiliacs fare far better today then a decade ago, thanks in large part to generous supplies of reasonably priced factor VIII and cryoprecipitate. Factor VIII is mainly supplied from commercial sources. Last year, for example, approximately 90% of the factor VIII produced in the United States came from paid sources.
The widening availability of factor VIII has facilitated home treatment and preventive maintenance, freeing hemophiliacs from the time, cost, and inconvenience of repeated emergency care and hospitalization. Their new freedom has in turn freed medical and nursing staffs to develop
Aledort LM. The Availability of Plasma Products and the Care of Hemophilia Patients. JAMA. 1981;246(2):157. doi:10.1001/jama.1981.03320020049025
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: